Skip to content

爵士制药

US · JAZZ #1123 按市值排名 上市于 1970
210.23 -4.19 -1.95%
实时 - 追踪5344个代码 - 心跳于529秒前 · 2026-10-16 20:02

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量增加了3家。
  • 机构持股总比例下降了0.6个百分点。

机构持股

机构持股比例
100.30% -0.61pp
机构数量
773 +3
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund80.85%
Hedge Fund11.02%
Individual/Insider2.89%
Public Company2.67%
Government Pension Fund1.61%
Private Company1.52%
Sovereign Wealth Fund1.01%
VC/PE Fund0.87%
Insurance Company0.41%

主要股东 截至 2026-06-30

BlackRock 9.19% · 5.97M 股
FMR 7.03% · 4.57M 股
Vanguard Capital Management, LLC 4.81% · 3.12M 股
Vanguard Portfolio Management, LLC 4.68% · 3.04M 股
Capital Research 4.16% · 2.70M 股
LSV Asset Management 3.50% · 2.28M 股
Franklin Resources 3.14% · 2.04M 股
State Street Global Advisors 3.08% · 2.00M 股
Dimensional Fund Advisors 2.64% · 1.71M 股
Fuller & Thaler Asset Management, Inc. 2.52% · 1.64M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 13次买入 · 37次卖出

姓名职务持股比例
Seamus Mulligan Independent Director 1.98%
Bruce Cozadd Chairperson & CEO 0.48%
Renee Gala President 0.08%
Kenneth O’Keefe Independent Director 0.04%
Robert Iannone Executive VP and Global Head of Research & Development 0.04%
Philip Johnson Chief Financial Officer 0.04%
Samantha Pearce Senior Vice President of Europe & International 0.03%
Neena Patil Chief Legal Officer 0.03%
Patrick Gerald Enright Independent Director 0.03%
Heather McSharry Independent Director 0.03%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-30 Bruce Cozadd Chairperson & CEO Automatic Disposition -6,000 $230.33
2026-09-09 Neena Patil Chief Legal Officer Automatic Disposition -1,200 $240.94
2026-09-07 Renee Gala President Sale to Issuer -1,967 $246.81
2026-09-07 Renee Gala President Automatic Disposition -2,000 $243.03
2026-09-07 Mary Henderson Senior Vice President of Technical Operations Sale to Issuer -1,427 $241.20–243.03
2026-08-31 Bruce Cozadd Chairperson & CEO Automatic Disposition -6,000 $250.13
2026-08-30 Bruce Cozadd Chairperson & CEO Sale to Issuer -1,219 $241.39–244.06
2026-08-30 Norbert Riedel Independent Director Sale to Issuer -1,706 $241.39–244.64
2026-08-30 Ted Love Director Sale to Issuer -743 $241.39–244.06
2026-08-30 Patrick Gerald Enright Independent Director Sale to Issuer -1,706 $241.39–244.64
2026-08-30 Patrick Kennedy Independent Director Sale to Issuer -1,855 $241.39–244.06
2026-08-30 Rick Winningham Lead Independent Director Sale to Issuer -1,706 $241.39–244.64
2026-08-30 Jennifer Cook Independent Non-Executive Director Sale to Issuer -1,706 $241.39–244.06
2026-08-30 Laura Hamill Independent Director Sale to Issuer -1,706 $241.39–244.06
2026-08-30 Heather McSharry Independent Director Sale to Issuer -1,855 $241.39–244.64
2026-08-30 Mark Smith Independent Non-Executive Director Sale to Issuer -1,706 $241.39–244.64
2026-08-30 Mary Henderson Senior Vice President of Technical Operations Sale to Issuer -2,092 $241.39–244.64
2026-08-26 Robert Iannone Executive VP and Global Head of Research & Development Automatic Disposition -19,421 $250.60–252.76
2026-08-26 Robert Iannone Executive VP and Global Head of Research & Development Derivative Exercise and Sale -57,500 $113.10–250.60
2026-08-06 Anne O'Riordan Independent Director Intent to Sell (Form 144) -3,507 $251.58

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:02:10 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

爵士制药 讨论区 0 条评论

发表评论